Abstract
Patients with mNSCLC without actionable driver mutations have limited treatment options after progression on concurrent or sequential front-line immune checkpoint inhibitors (ICI) and platinum-based chemotherapy ± bevacizumab. LN-145, an autologous TIL cell therapy, has demonstrated feasibility, safety, and an early signal of efficacy with a 21.4% objective response rate (ORR) in heavily pretreated patients with mNSCLC, including responders with PD-L1-negative tumors (Schoenfeld AJ, SITC 2021 [abs 458]).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
